Drug Approval | September 21, 2022
Tezspire approved in the EU for the treatment of severe asthma
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
It is the first branded generic alternative to Fostair 100/6 pMDI
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Subscribe To Our Newsletter & Stay Updated
